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Abstract
Antineutrophil cytoplasmic autoantibody (ANCA)-associated small-vessel vasculitis frequently
affects the kidney. Here we describe the rates of infection, disease relapse, and death in patients with
ANCA small-vessel vasculitis before and after end-stage renal disease (ESRD) in an inception cohort
study and compare them to those of patients with preserved renal function. All patients had biopsy-
proven ANCA small-vessel vasculitis. Fisher's exact tests and Wilcoxon rank sum tests were used
to compare the characteristics by ESRD status. ESRD follow-up included time on dialysis with
transplants censored. Over a median follow-up time of 40 months, 136 of 523 patients reached ESRD.
ESRD was associated with new-onset ANCA small-vessel vasculitis in 51% of patients, progressive
chronic kidney disease without active vasculitis in 43%, and renal relapse in 6% of patients. Relapse
rates of ANCA small-vessel vasculitis, reported as episodes/person-year, were significantly lower
on chronic dialysis (0.08 episodes) compared with the rate of the same patients before ESRD (0.20
episodes) or with patients with preserved renal function (0.16 episodes). Infections were almost twice
as frequent among patients with ESRD on maintenance immunosuppressants and were an important
cause of death. Given the lower risk of relapse and higher risk of infection and death, we suggest
that immunosuppression be geared to patients with ESRD who present with active vasculitis.
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Antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis (ANCA-SVV)
frequently affects the kidneys, causing a destructive pauci-immune necrotizing and crescentic
glomerulonephritis. Despite improved therapies and outcomes,1–4 ANCA-SVV still results in
end-stage renal disease (ESRD) in a quarter of patients over 3–4 years.3,5,6 Information on the
course of ANCA-SVV while on chronic dialysis is relatively scant. Risk factors for relapse
have been described for patients with ANCA-SVV,3 but it is not clear whether they apply to
the prediction of relapse after ESRD is reached. Knowledge about risk and severity of relapse
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is crucial in determining the need for maintenance immunosuppression. This is of particular
importance as the rate of infections is significantly higher among patients on dialysis.7
Chronic dialysis may result in a relative quiescence of the autoimmune process.8–11 It has thus
been reported that the relapse rate of ANCA-SVV among patients on chronic dialysis is
substantially lower compared with that among patients with preserved renal function.7,12 It is
not clear whether this reduced rate of relapse is attributable to continued immunosuppression
or simply reflects the natural progression of this disease. Fear of disease relapse has led to the
use of preventive maintenance immunosuppressive therapy irrespective of the need for dialysis.
7,13 However, morbidity associated with dialysis demands that any benefit from
immunosuppression outweighs the risks. If ANCA-SVV disease activity and relapses decrease
on chronic dialysis, prolongation of immunosuppression after ESRD may be associated with
more risk than benefit.
On the basis of a large inception observational cohort of patients with ANCA-SVV, we describe
the clinical course of dialysis-dependent patients compared to patients with preserved renal
function with respect to the cause of ESRD, the disease activity, frequency of relapse,
morbidity, and mortality.
RESULTS
Description of the ANCA-SVV ESRD and non-ESRD groups
Of the 523 ANCA-positive patients with biopsy-proven ANCA-SVV in our registry, 95 needed
dialysis at initial presentation. Of these, 40 remained dialysis dependent or died during the first
3 months, and 55 recovered enough renal function to discontinue dialysis. As of 1 October
2007, we identified 136 patients who had reached ESRD (ESRD group) and 387 patients with
preserved renal function (non-ESRD group). No clinical information after the start of dialysis
was available for 43 patients in the ESRD group; therefore, they were excluded from the
analyses. Likewise, 28 patients (7%) with preserved renal function were excluded because of
limited follow-up (recently diagnosed cases or lost to follow-up) (Figure 1). The median
observation time for the ESRD group, including time after ESRD, was 63 months (interquartile
range (IQR): 13–75 months) and for the non-ESRD group was 40 months (IQR: 15–55 months).
Demographics
As shown in Table 1, demographics, and baseline and disease-related characteristics of the
total ESRD group (n = 136) were similar to those of the ESRD group with available follow-
up (n = 93). As a consequence, we considered the latter group representative of the total ESRD
group and based estimates and comparisons on this subgroup.
All patients in the ESRD group and 87% in the non-ESRD group had biopsy-proven
glomerulonephritis. No significant differences were observed in the distribution of gender and
race, with a predominance of Caucasians in both groups (84 and 87%, respectively). Mean age
at diagnosis of ANCA-SVV was 56 years in both groups.
In the ESRD group, mean age at initiation of chronic dialysis was 58 years. Over the follow-
up time with renal failure, the majority of patients received hemodialysis (n = 83 and 89%),
whereas only a minority were treated at any time with peritoneal dialysis (n = 31 and 33%) or
had a kidney transplant (n = 19 and 20%).
Characteristics related to ANCA-SVV
The mean Birmingham Vasculitis Activity Score14 (BVAS) at initiation of chronic dialysis
was 7.75 ± 8.05, whereas 51.5% of the patients had active disease in at least one organ (BVAS
Lionaki et al. Page 2













> 1). All patients in the ESRD group (n = 136) were further categorized with respect to the
phase of ANCA-SVV, which led to ESRD (Table 2). Sixty-nine patients (51%) reached ESRD
due to new-onset ANCA glomerulonephritis (BVAS = 13.76 ± 5.98), with 51 dialysis
dependent at presentation and 12 who progressed to renal failure without attaining a remission.
Of the 51 patients who required dialysis at presentation, 7 were not treated, whereas the
remaining 44 received immunosuppressive therapy. Relapsing disease involving the kidney
led to ESRD in eight cases (6%) (BVAS = 7.50 ± 5.92). Fifty-eight patients (43%) reached
ESRD due to progressive chronic kidney disease without evidence of active ANCA
glomerulonephritis (BVAS = 0) (Tables 1 and 2). Mean time from diagnosis to ESRD in these
patients was 24 months (IQR: 12–45 months).
Myeloperoxidase ANCA (MPO-ANCA) was more frequent in the ESRD group (61%) than in
the non-ESRD group (53%), but this difference was not statistically significant (P = 0.25). The
ESRD group comprised a higher proportion of patients with renal-limited disease (33%) and
a lower proportion of patients with Wegener's granulomatosis (15%) compared with the non-
ESRD group (20 and 27%, respectively; P = 0.0104) (Table 3). A total of 66 ESRD patients
(71%) had at least one risk factor previously associated with relapse in a subset of the overall
cohort3 (PR3-ANCA positive, pulmonary or upper respiratory involvement), which was
similar to the overall group where 274 (76%) had at least one of these risk factors.
Regarding organ involvement, all patients within the ESRD group and 94% of patients in the
non-ESRD group exhibited kidney involvement at some point, but entry serum creatinine was
significantly higher in the ESRD group (P < 0.0001). Lung involvement was present with
similar frequency, whereas upper respiratory tract involvement was more frequent among the
non-ESRD patients.
Compared with the non-ESRD group, more patients in the ESRD group received no
immunosuppression (6 versus 2%) and corticosteroids alone (14 versus 8%), whereas fewer
in the ESRD group received treatment with combined therapy with corticosteroids and
cyclophosphamide (CYC) (75 versus 84%) either orally or intravenously at the time of
diagnosis (P = 0.007) (Table 3). Patients in the ESRD group received CYC for a shorter duration
(6.6 ± 7.5 months) than did patients in the non-ESRD group (9.1 ± 9.4 months, P = 0.0002).
Treatment resistance was more common in the ESRD group (56%) than in the non-ESRD group
(8%; P < 0.0001).
Among the ESRD patients, we compared those who required dialysis within 1 month of
diagnosis of ANCA-SVV with the patients who reached ESRD later, as a result of relapse or
a progressive decline in glomerular filtration rate without active vasculitis or
glomerulonephritis (Table 4). Patients with ESRD from new-onset ANCA glomerulonephritis
had higher levels of serum creatinine (8.6 ± 4.2 versus 5.3 ± 3.5 mg per 100 ml, P < 0.0001),
received treatment with CYC for a shorter period (2.9 ± 3.0 versus 8.4 ± 7.9 months, P <
0.0001), and were more frequently resistant to therapy (86 versus 25%, P < 0.0001) (Table 4).
Relapse rates of ANCA-SVV before and after ESRD
Relapse rates of ANCA-SVV were estimated before and after initiation of chronic dialysis,
and for the non-ESRD group. In the ESRD group, relapses occurred at a rate of 0.20 episodes
per person-year (95% confidence interval (CI): 0.13–0.26) before dialysis, which was similar
to the rate of 0.16 episodes per person-year (95% CI: 0.13–0.17) for the non-ESRD group (P
= 0.20). When the non-ESRD group was limited to only patients with renal involvement (n =
339), the relapse rate was similar (0.15 episodes per person-year; 95% CI: 0.14–0.17). Post
ESRD, the relapse rate was 0.08 per person-year (95% CI: 0.04–0.11), which was significantly
lower than the pre-ESRD rate (P = 0.0012) (Table 3). Similarly, the exclusion of patients with
renal-limited ANCA-SVV did not significantly impact the relapse rate in the non-ESRD group
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(0.17 episodes per person-year; 95% CI: 0.15–0.19) or the relapse rates before and after ESRD
(0.20 and 0.08 episodes per person-year, respectively) in the ESRD group.
Among patients who reached ESRD, the relapse rate pre and post ESRD was calculated
separately for the subgroups of patients with PR3- and MPO-ANCA (Table 5). For patients
with PR3-ANCA, the rate of relapse decreased significantly from 0.34 (95% CI: 0.25, 0.42)
episodes per person-year pre ESRD to 0.11 (95% CI: 0.04, 0.18) post ESRD (P = 0.0015). For
patients with MPO-ANCA, the rates of relapse were low and did not change significantly pre
and post ESRD (0.06 (95% CI: 0.004, 0.12) and 0.04 (95% CI: 0.002, 0.076), respectively
(P = 0.47)).
Ten (11%) patients experienced 14 vasculitis relapses after the start of dialysis corresponding
to an incidence rate of 0.25 relapses per patient-year (95% CI: 0.17, 0.33). These 10 patients
had had a total of eight relapses pre ESRD (0.40 relapses per patient-year (95% CI: 0.26, 0.53)).
Three of them had ESRD due to new-onset vasculitis, one due to relapse, and six due to chronic
kidney damage. Five of the 14 post-ESRD relapses occurred while the patients were on
maintenance immunosuppressive therapy. Organ systems affected by relapses included the
lungs (n = 8), upper respiratory tract (n = 3), skin (n = 2), musculoskeletal system (n = 3), and
the eye (n = 1). The mean BVAS at relapse was 8.9, excluding three cases for which insufficient
information was available for scoring. Immunosuppressive treatment was instituted in 11 of
14 occurrences. Of the three untreated patients, one had unrecognized active vasculitis that
was detected on autopsy and one had upper respiratory tract disease managed with a local
procedure. The third was an elderly patient with only mild skin manifestations. Relapse
outcomes included complete or partial remission in eight patients, death in five (including the
relapse detected at autopsy), and an unknown outcome in one patient.
Adverse events
Three hundred and fifty-four episodes of infections occurred in 61 patients on chronic dialysis
corresponding to an incidence rate of 1.92 episodes per person-year. Infectious episodes
included the respiratory and urinary tracts, the skin, dialysis access sites, bacteremia of
unknown origin, and peritonitis. The rate of infection was significantly higher among
immunosuppressed patients (1.94 episodes per person-year; 95% CI: 1.61–2.26) than among
those not receiving immunosuppressive therapy (1.03 episodes per person-year; 95% CI: 0.87,
1.19; P < 0.0001).
Eight malignancies were diagnosed in five patients in the ESRD group, resulting in an incidence
rate of 0.04 episodes per patient-year (95% CI: 0.01–0.07), which was statistically higher than
that in the non-ESRD group where 15 malignancies were found in 15 patients, resulting in a
rate of 0.01 episodes per person-year (95% CI: 0.007–0.02, P = 0.046) (Table 3).
Mortality rate and patient survival before and after ESRD
In the ESRD group, 59 deaths occurred, corresponding to a mortality rate of 0.31 deaths per
person-year (95% CI: 0.26–0.36). Deaths occurred in a median of 43 months from diagnosis
of ANCA-SVV and 37 months from the start of chronic dialysis. Causes of death were known
in 21 of the ESRD cases, and were attributed to infection (n = 9), active vasculitis (n = 5),
cardiovascular disease (n = 3), malignancy (n = 3), and withdrawal from dialysis (n = 1). Within
a month of diagnosis, the predominant cause of death was active vasculitis (4 of 5 deaths),
whereas subsequent deaths were primarily due to infections (8 of 16 deaths). Death rate among
patients who reached ESRD with active vasculitis (new-onset disease or relapse) (37 of 56,
66%) was similar compared with those who reached ESRD with no active vasculitis (22 of 37,
60%, P = 0.66). However, the incidence of death among patients with ESRD from new-onset
disease (0.86 deaths per patient-year; 95% CI: 0.70, 1.01) was significantly higher than that
Lionaki et al. Page 4













for those who reached ESRD later (0.16 deaths per patient-year; 95% CI: 0.12, 0.21)
corresponding to an incidence ratio of 5.22 (95% CI: 3.79, 7.21). One-year and 5-year survival
rates were 77 and 28%, respectively, for the ESRD group (from disease onset). The proportion
of patients with ESRD who died was similar for the three disease categories (63% of patients
with either renal-limited disease or microscopic polyangiitis, 65% of patients with Wegener's
granulomatosis).
In the non-ESRD group, 76 deaths occurred corresponding to a significantly lower mortality
rate (0.07 deaths per person-year; 95% CI: 0.05–0.08; P < 0.0001) than in the ESRD group
(0.27, 95% CI: 0.21–0.32 per person-year). Cause of death was unknown in 55 patients. In the
21 with known causes, death was attributed to vasculitis (n = 7), cardiovascular disease (n =
6), malignancy (n = 5), and infections (n = 3). One-year and 5-year survival rates were 92 and
71%, respectively.
DISCUSSION
Despite the improved therapy of ANCA-SVV over the past 2 decades, the frequency of ESRD
remains elevated. In our patient population, 26% of patients reached ESRD over a median of
34 months (IQR: 12–75 months). It is noteworthy that 94% of patients who reached ESRD did
so in one of two settings: presentation with advanced renal failure requiring dialysis at or near
the time of diagnosis, or progression to ESRD without evidence of active glomerulonephritis
or vasculitis over a median of 24 months. Eighty percent of patients who required dialysis near
diagnosis presented with severe renal insufficiency (mean entry serum creatinine of 8.6 mg
per 100 ml) and remained dialysis dependent despite the institution of appropriate
immunotherapy with corticosteroids and CYC. This underscores the importance of early
diagnosis and prompt treatment to attain recovery of renal function before renal scarring has
occurred. It is worth noting that the majority of patients presented before plasmapheresis was
used routinely for patients presenting with advanced renal disease,15 which may decrease the
frequency of irreversible dialysis dependence in the future.
In our cohort, there was a higher representation of patients with renal-limited disease in the
dialysis-dependent group compared with that in the non-ESRD group. In the absence of
extrarenal manifestation of disease, patients may not seek medical attention until they develop
uremic symptoms associated with advanced renal scarring and a limited chance of recovery.
This concept is supported by our finding that patients who require dialysis at or near diagnosis
presented with significantly higher serum creatinine levels. It is also supported by previous
correlations of poor renal prognosis with histological markers of chronic scarring.3,16,17
Comparison of initial therapy between the ESRD and non-ESRD groups reveals a higher
frequency of patients who did not receive immunosuppressive therapy, and a shorter duration
of treatment with CYC in the dialysis-dependent group. The higher frequency of non-treated
patients reflects the perception that, in patients with advanced renal failure and no extrarenal
vasculitis, the risk of immunosuppressive therapy outweighs the potential benefit. However, a
recent cohort analysis showed that there was no glomerular filtration rate below which
treatment was futile.3 Similarly, a subgroup analysis of patients presenting with advanced renal
failure participating in the MEPEX study revealed that therapeutic futility is seen only when
2% or fewer of glomeruli are normal.4
The finding of a shorter initial course of CYC among the ESRD group is a result rather than a
cause of dialysis dependence. In the absence of extrarenal manifestations, cytotoxic therapy is
usually discontinued when dialysis dependence continues beyond 3 months. Renal function is
not likely to recover beyond that point,6,18–20 whereas continuing cytotoxic therapy is
associated with serious infections and death.20
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An important issue to address is whether dialysis-dependent patients should receive
maintenance immunosuppression for relapse prevention. This decision should be based on an
assessment of the risk of continued immunosuppression relative to that of relapse. In our cohort,
patients with ESRD had a significantly lower relapse rate after the start of dialysis (0.08
episodes per person-year) than that before (0.20 episodes per person-year). Differences in
relapse rates between those on dialysis and those pre dialysis have also been reported by
Weidanz et al.7, with a rate after dialysis of 0.13 per person-year (95% CI: 0.07, 0.19) and
before dialysis of 0.40 per person-year (95% CI: 0.15, 0.98). This lower rate on dialysis reflects
only extrarenal relapses, as recurrent or persistent glomerulonephritis is essentially
undetectable once ESRD is reached. It may also reflect changes of the autoimmune response
in ESRD, as has been suggested for systemic lupus erythematosus.8–11 Our relapse rate among
patients with ESRD is similar to that reported in other cohorts (0.0912 and 0.137 per person-
year), but substantially lower than that reported by Haubitz et al.13 (0.24 per person-year)
among 35 patients with Wegener's granulomatosis who reached ESRD.
The lower rate of relapse after ESRD occurs in the context of a high rate of infections, especially
among patients on maintenance immunosuppressants, whose rate was almost twice that of
patients not receiving such treatments. Although the total number of vasculitic flares in our
ESRD group was too small (14 events in 10 patients) to formally assess the effect of
maintenance immunosuppression on relapse, our findings suggest that the risks of maintenance
immunosuppression outweigh the potential benefit among patients with ESRD. We contend
that immunosuppressive therapy should be restricted to patients with clinical evidence of active
extrarenal manifestation of vasculitis.
The 1-year survival rate of 77% for patients in the ESRD group is comparable with rates of
64–83% reported in other cohorts.5–7,7,12,13 In our cohort, the survival rates were over four
times worse in the ESRD group compared with those in the non-ESRD group, which is similar
to previous reports.6 The 1-year and 5-year survival rates for patients with ANCA-SVV and
ESRD (77 and 28%, respectively) are also considerably worse compared with survival rates
for adult patients with ESRD from all causes (90 and 48%, respectively).21 The excess mortality
among ANCA-SVV ESRD patients is likely attributable to a combination of sequelae of
systemic vasculitis, long-term effects of therapy with corticosteroids, CYC and other
immunosuppressants, and older age. The significantly higher incidence of death among the
patients with ESRD from new-onset disease compared with that of patients reaching ESRD
late in their course of disease likely reflects early deaths from severe active vasculitis.
One may argue that a limitation of this study pertains to the composition of our cohort of
patients with ANCA-SVV with a large predominance of patients with glomerulonephritis,
which may reflect a lower rate of relapse. However, it is unlikely that the small number of
disease flares after ESRD were due to an over-representation of patients at low risk (for
example, patients with renal-limited disease) as 71% had at least one risk factor of relapse
(50% with lung involvement, 28% with upper respiratory tract disease, and 39% PR3-ANCA
positive). In addition, the significant decrease in the rate of relapse post ESRD we observed is
not due to an over-representation of patients with MPO-ANCA among patients with ESRD,
as this decrease in relapse rate was primarily seen among patients with PR3-ANCA.
Furthermore, we report a sharp decrease in the rate of relapses after ESRD (compared with
that before) based on the same population, which excludes any effect of the cohort composition
on the relapse rate post ESRD. Unfortunately, the small number of disease flares does not allow
assessment of the influence of these three risk factors on relapse in the population of patients
with ESRD.
Other limitations to our study include retrospective BVAS scoring, incomplete data on the
causes of death, and possibly incomplete reporting of serious infections. The latter, however,
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would result in an underestimation of the importance of infections in the outcome of patients
with ANCA vasculitis and ESRD. For lack of suitable local or regional data, we were also
unfortunately unable to compare the all-cause and cardiovascular mortality of patients with
ANCA vasculitis and ESRD with that of a control population of patients with ESRD,
controlling for age and race.
In summary, despite advances in treatment, a quarter of patients with ANCA-SVV still suffer
from ESRD. ESRD is largely contributed to by new-onset disease with severe renal failure,
rather than by persistent or relapsing vasculitis, underscoring the need for prompt diagnosis
and therapy. Faster recognition of ANCA-SVV and implementation of a more effective therapy
may help reduce the burden of ESRD. Patients with ANCA-SVV and ESRD experience a low
rate of relapses, but are at high risk of infectious complications associated with significant
morbidity and mortality. These observations support the judicious use of immunosuppression
in patients with ANCA-SVV ESRD, with restriction to use only in the setting of active
vasculitis.
MATERIALS AND METHODS
Description of patient population and definitions
Patients enrolled in the ANCA-SVV registry as of 1 October 2007 were eligible to be included
in this inception cohort study, which was started in 1986. Registry patients were identified at
or near initial diagnosis and fulfilled three criteria: native kidney biopsy showing pauci-
immune ANCA glomerulonephritis with or without granulomatous inflammation and/or
biopsy on any other tissue showing pauci-immune SVV (n = 27; predominantly the lung, sinus,
and skin), positive ANCA determination by immunofluorescence microscopy or antigen-
specific enzyme-linked immunosorbent assay,22 and signed informed consent for review of
medical records. ANCA positivity was further classified as cytoplasmic ANCA and/or anti-
proteinase-3 (anti-PR3) ANCA, or perinuclear ANCA and/or anti-myeloperoxidase ANCA
(anti-MPO) or both. A perinuclear ANCA alone required a concurrent negative antinuclear
antibody test.23,24 Renal biopsy specimens were evaluated by the University of North Carolina
Nephropathology Laboratory and patients were followed by physicians of the Glomerular
Disease Collaborative Network. The Glomerular Disease Collaborative Network and subsets
of the ANCA-SVV registry have previously been described elsewhere.3,18,19
Diagnostic ANCA-SVV categories were defined according to the Chapel Hill Consensus
Conference.23 A diagnosis of Wegener's granulomatosis was defined by the presence of
necrotizing granulomatous inflammation in any tissue by histology, and/or imaging showing
pulmonary nodules or cavities (non-infectious) and/or bony erosions, and/or subglottic stenosis
in the upper respiratory tract. Churg–Strauss syndrome was defined by the presence of asthma,
eosinophilia, and necrotizing granulomatous inflammation. Microscopic polyangiitis was
defined by systemic necrotizing SVV without evidence of granulomatous inflammation or
asthma.23,25
Organ involvement was defined by biopsy or by previously described criteria.18,19 BVASs
were determined from a review of medical records. Treatment categories were determined by
the regimen used at diagnosis and included no therapy, corticosteroids alone, or corticosteroids
in combination with CYC or other immunosuppressive therapies.3,18 Duration of
immunosuppressive therapy was recorded but patients were considered as treated with a given
regimen independent of duration.
Outcomes of interest included treatment resistance, remission on or off therapy, relapse, ESRD,
and death, as previously described.3,18 In brief, outcomes after the initial diagnosis of ANCA-
SVV were determined as treatment resistance, remission on therapy, remission off therapy,
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relapse, and ESRD. Treatment resistance was defined as a progressive decline in kidney
function with persistence of active urine sediment or new or persistent extrarenal
manifestations of vasculitis despite immunosuppressive treatment. Resistance to therapy was
determined after at least 1 month of therapy. Remission was defined as the stabilization or
improvement of kidney function as measured by serum creatinine levels and resolution of
hematuria or other manifestations of systemic vasculitis for more than 1 month. The persistence
of proteinuria was not considered indicative of active glomerulonephritis. Remission off
therapy was defined as remission with no therapy or with less than 7.5 mg prednisone per day.
Relapse could only be recorded among responders (the patients who had achieved remission
either on or off therapy) and included recurrent or new signs and symptoms of active vasculitis
in any organ.
The cohort of patients with ANCA-SVV was divided into two groups (Figure 1): (1) patients
who had reached ESRD, at or any time after the diagnosis of ANCA-SVV, and then maintained
on chronic renal replacement therapy (ESRD group) and (2) those with a preserved renal
function (non-ESRD group). Three patients who underwent kidney transplantation promptly
after the diagnosis of ESRD were excluded. Patients who required acute dialysis at or after the
diagnosis of ANCA-SVV, but subsequently recovered renal function and were dialysis free as
of 1 October 2007, were included in the non-ESRD group. Conversely, patients who were
dialysis dependent at presentation and never came off were included in the ESRD group.
Dialysis dependency at presentation was considered in cases with severe renal insufficiency
requiring dialysis at, or within, 30 days of diagnosis. The start of chronic dialysis was
determined as the date when dialysis was initiated with no subsequent interruption. As our
ANCA-SVV database includes information until death or ESRD, and for the purposes of this
study, a detailed supplemental clinical information was sought from the treating nephrologists
for all cases in the ESRD group from the onset of dialysis to kidney transplantation or death.
All patients in the ESRD group were categorized with respect to the phase of ANCA-SVV at
the point they reached ESRD. Hence, each patient could be classified as having reached ESRD
due to one of three reasons: (1) new-onset ANCA glomerulonephritis, which primarily includes
those who presented at or near dialysis and those patients who were treatment resistant, (2)
relapse of ANCA-SVV involving the kidney, which led to ESRD, or (3) progressive chronic
kidney disease without evidence of active ANCA glomerulonephritis for greater than 6 months.
In cases with ANCA-SVV and ESRD, any symptoms or signs were considered vasculitic in
origin if they had been observed for a month or more after the initiation of dialysis, to
differentiate them from uremic symptoms. We recorded all relapses of ANCA-SVV on chronic
dialysis, the organs involved, the type and duration of, and response to, prescribed
immunosuppressive therapy. Vasculitic activity was assessed using the BVAS system.14
Infections in the ESRD group were determined as those requiring hospitalization. For
comparison of infection rates by use of immunosuppressive therapy, a minimum of 1 month
of immunosuppressive therapy after the onset of dialysis was required. Malignancies were
assessed by review of medical records. Death was documented from available medical records
or from the Social Security Death index (http://ssdi.rootsweb.ancestry.com/cgi-bin/ssdi.cgi).
Statistical methods
Descriptive statistics include n, percent, mean, s.d., and IQR. Demographics and clinical
characteristics were compared between patients who reached ESRD and those who did not
reach ESRD using Fisher's exact tests for categorical measures and Wilcoxon rank sum tests
for continuous measures. The same tests were used to compare clinical characteristics between
subgroups of ESRD patients. In instances where continuous measures were compared across
more than two patient groups, Kruskal–Wallis tests were used. Incidence rates were calculated,
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taking into account the varying follow-up times, and are reported as per patient-year of follow-
up using all events for relapse, infection, malignancies, and mortality. The binomial principles
were used to calculate 95% CIs and s.d. for incidence rates. P-values for comparing two
incidence rates were calculated by testing the hypothesis that their difference was equal to zero.
Kaplan–Meier estimators were used to estimate the probability of ESRD-free survival.
Analyses were conducted using SAS 9.1 (SAS Institute, Cary, NC, USA). Exact P-values are
reported with a two-sided P-value of 0.05 or less considered statistically significant.
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Table 1
Characteristics of patients with ANCA-SVV who reached ESRD
Characteristic All ANCA-SVV/ESRD ANCA-SVV/ESRD with available
long-term information
n (%) or mean ± s.d. n=136 n=93
Age at diagnosis (years) (± s.d.) 57 ± 21 56 ± 22
Gender, female (%) 67 (49%) 47 (51%)
Race
    Caucasian 113 (83%) 78 (84%)
    Other 23 (17%) 15 (16%)
ANCA typea
    PR3 or C-ANCA 45 (34%) 35 (39%)
    MPO- or P-ANCA 88 (66%) 55 (61%)
Disease category
    WG 19 (14%) 14 (15%)
    MPA 67 (49%) 48 (52%)
    RL 49 (36%) 30 (32%)
    CSS 1 (1%) 1 (1%)
Organ involvement, ever
    Lung 63 (46%) 47 (51%)
    ENT 36 (27%) 26 (28%)
Initial treatmentb
    No treatment 12 (9%) 6 (7%)
    Corticosteroids alone 23 (17%) 13 (14%)
    Prednisone + CYC 96 (72%) 70 (77%)
    Other 2 (2%) 2 (2%)
Age at initiation of ESRD (years) 58 ± 21 57 ± 22
Duration of disease,# months (± s.d.) 16.6 ± 27.01 16.9 ± 28.8
Median 3.45 2.4
IQR 0.03, 24.01 0.0, 24.01
BVAS at diagnosis of ESRD (± s.d.) 7.75 ± 8.05 8.21 ± 8.25
ANCA-SVV, antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis; BVAS, Birmingham Vasculitis Activity Score; CSS, Churg–
Strauss syndrome; CYC, cyclophosphamide; ENT, ear, nose, and throat; ESRD, end-stage renal disease; MPA, microscopic polyangiitis; RL, renal-limited
disease; WG, Wegener's granulomatosis.
#
Duration of disease before ESRD among patients who reached ESRD and for the full duration of follow-up for the non-ESRD group.
a
Three patients were reported as 'ANCA positive,' but had missing information on ANCA specificity. These three patients were among those with long-
term follow-up information.
b
Three patients had missing information on initial treatment, two of whom were among those with long-term follow-up information.
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Table 2
Summary of cause and disease activity among patients reaching ESRD
ESRD subgroup n (%) % With active disease BVAS (mean ± s.d.)
ESRD groupa 136 51.5 7.75 ± 8.05
    New-onset GN 69 (51%) 100 13.76 ± 5.98
    Relapsing GN 8 (6%) 100 7.50 ± 5.92
    Progressive CKD without active vasculitis 58 (43%) 0 0
BVAS, Birmingham Vasculitis Activity Score; CKD, chronic kidney disease; ESRD, end-stage renal disease; GN, glomerulonephritis.
a
One unknown ESRD cause.
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Table 3
Comparison of the ANCA-SVV ESRD and non-ESRD groups
Characteristica ANCA-SVV ESRD ANCA-SVV non-ESRD
n (%), mean ± s.d., rate with 95% CI, or median and
IQR, as noted
n=93 n=359 P-value
Age at diagnosis (years) 56 ± 22 56 ± 18 0.32
Gender, female (%) 47 (51%) 164 (46%) 0.53
Race
    Caucasian 78 (84%) 312 (87%) 0.80
    Non-Caucasian 15 (16%) 47 (13%)
ANCA type
    PR3 or C-ANCA 35 (39%) 164 (47%) 0.25
    MPO- or P-ANCA 55 (61%) 188 (53%)
Disease category
    WG 14 (15%) 97 (27%) 0.0104
    MPA 48 (52%) 187 (53%)
    RL 30 (33%) 72 (20%)
Organ involvement
    Kidney 93 (100%) 339 (94%) 0.0193
    Lung 47 (51%) 187 (52%) 0.82
    ENT 26 (28%) 143 (40%) 0.04
Peak serum creatinine at onset (± s.d.) (mg per 100
ml)
6.9 ± 4.5 3.7 ± 2.8 <0.0001
Initial treatment
    No treatment 6 (6%) 8 (2%) 0.007
    Corticosteroids alone 13 (14%) 29 (8%)
    Prednisone + CYC 70 (77%) 300 (84%)
    Other 2 (2%) 22 (6%)
Treatments with CYC, months 6.6 ± 7.5 9.1 ± 9.4 0.0002
Treatment resistant 52 (56%) 29 (8%) <.0001
ANCA-SVV pre-ESRD 0.20 (0.13–0.26) 0.16 (0.13–0.17) 0.20




Malignancy rate, episodes per person-year (95%
CI)
0.04 (0.01–0.07) 0.01 (0.007–0.02) 0.046
Patients with malignancy 5 (5%) 15 (4%)
Total number of malignancies 8 15
Mortality rate (deaths/person-year) 0.31 (0.26–0.36) 0.07 (0.05–0.08) <0.0001
Deaths, total number (%) 59 (63%) 76 (21%)
Median follow-up time in months (IQR) 63 (13–75) 40 (15–55)
ANCA-SVV, antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis; BVAS, Birmingham Vasculitis Activity Score; CI, confidence
interval; CSS, Churg–Strauss syndrome; CYC, cyclophosphamide; ENT, ear, nose, and throat; ESRD, end-stage renal disease; IQR, interquartile range
(25th and 75th percentile); MPA, microscopic polyangiitis; NA, not applicable; RL, renal limited disease; WG, Wegener's granulomatosis.
a
One to three values were missing for each variable and were excluded from estimates and comparison tests.
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Table 4
Characteristics of the patients with ANCA-SVV and ESRD in association with phase of ANCA
glomerulonephritis that led to chronic renal failure
ANCA-SVV/ESRD, n=136 New-onset disease, n=69a Relapse or CKD, n=66a P-value
Peak entry creatinine (± s.d.) 8.6 ± 4.2 5.3 ± 3.5 <0.0001
Treatment with CYC, months (± s.d.) 2.9 ± 3.0 8.4 ± 7.9 <0.0001
Treatment resistant (%) 59 (86%) 16 (25%)b <0.0001
Median time from ANCA-SVV diagnosis to
ESRD in months, median (IQR)
0.03 (0–0.9) 24 (10–39) <0.0001
ANCA-SVV, antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis; CYC, cyclophosphamide; ESRD, end-stage renal disease; IQR,
interquartile range.
a
One patient with unknown disease status when reached ESRD.
b
Two missing values for treatment resistance.
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